BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen H, Yang M, Wang Q, Song F, Li X, Chen K. The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. Oncoimmunology 2019;8:1608132. [PMID: 31413919 DOI: 10.1080/2162402X.2019.1608132] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Mahdavi Gorabi A, Sadat Ravari M, Sanaei M, Davaran S, Kesharwani P, Sahebkar A. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. International Immunopharmacology 2022;113:109300. [DOI: 10.1016/j.intimp.2022.109300] [Reference Citation Analysis]
2 Wang L, Hu X, Liu X, Feng Y, Zhang Y, Han J, Liu X, Meng F. m7G regulator-mediated methylation modification patterns define immune cell infiltration and patient survival. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1022720] [Reference Citation Analysis]
3 Wang X, Wu L, Dou Q, Ai L, Lu Y, Deng S, Liu Q, Ji H, Zhang H. Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response. Front Mol Biosci 2022;9:1034928. [DOI: 10.3389/fmolb.2022.1034928] [Reference Citation Analysis]
4 Luo H, Ye M, Hu Y, Wu M, Cheng M, Zhu X, Huang K. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. Aging (Albany NY) 2022;14. [PMID: 36152044 DOI: 10.18632/aging.204291] [Reference Citation Analysis]
5 Xu L. Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast cancer. Front Immunol 2022;13:942765. [DOI: 10.3389/fimmu.2022.942765] [Reference Citation Analysis]
6 Tang TY, Huang X, Zhang G, Lu MH, Liang TB. mRNA vaccine development for cholangiocarcinoma: a precise pipeline. Mil Med Res 2022;9:40. [PMID: 35821067 DOI: 10.1186/s40779-022-00399-8] [Reference Citation Analysis]
7 Tan H, Yu T, Liu C, Wang Y, Jing F, Ding Z, Liu J, Shi H. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine. Cancer Med 2022;11:4656-72. [PMID: 35593226 DOI: 10.1002/cam4.4846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fan Y, Zhou Y, Lou M, Li X, Zhu X, Yuan K. m6A Regulator-Mediated Methylation Modification Patterns and Characterisation of Tumour Microenvironment Infiltration in Non-Small Cell Lung Cancer. JIR 2022;Volume 15:1969-89. [DOI: 10.2147/jir.s356841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
9 Yi L, Huang P, Gu Y, Wu G, Zou X, Guo L, Wen C, Zhu J, Zhao D. Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma. Front Oncol 2022;12:794293. [PMID: 35155238 DOI: 10.3389/fonc.2022.794293] [Reference Citation Analysis]
10 Zhu M, Cui Y, Mo Q, Zhang J, Zhao T, Xu Y, Wu Z, Sun D, Zhang X, Li Y, You Q. Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma. Front Immunol 2021;12:782551. [PMID: 34975871 DOI: 10.3389/fimmu.2021.782551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zhu H, Hu X, Feng S, Jian Z, Xu X, Gu L, Xiong X, Duan B. The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors. Oxidative Medicine and Cellular Longevity 2022;2022:1-42. [DOI: 10.1155/2022/6419695] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
12 Ji L, Peng P, Gui L, Yuan P, Qian W, Wang Y, Gao W, Ma B. CD24 Is a Superior Immunotherapeutic Target to PD-1 in a Mouse Model of Helicobacter-Induced Gastric Cancer. Gastro Hep Advances 2022;1:79-82. [DOI: 10.1016/j.gastha.2021.09.011] [Reference Citation Analysis]
13 Du F, Li H, Li Y, Liu Y, Li X, Dang N, Chu Q, Yan J, Fang Z, Wu H, Zhang Z, Zhu X, Li X. Identification of m6A Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma. Front Cell Dev Biol 2021;9. [DOI: 10.3389/fcell.2021.761134] [Reference Citation Analysis]
14 Baltussen JC, Welters MJP, Verdegaal EME, Kapiteijn E, Schrader AMR, Slingerland M, Liefers G, van der Burg SH, Portielje JEA, de Glas NA. Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. Cancers 2021;13:6366. [DOI: 10.3390/cancers13246366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wu Y, Zhang X, Feng H, Hu B, Deng Z, Wang C, Liu B, Luan Y, Ruan Y, Liu X, Liu Z, Liu J, Wang T. Exploration of Redox-Related Molecular Patterns and the Redox Score for Prostate Cancer. Oxid Med Cell Longev 2021;2021:4548594. [PMID: 34804366 DOI: 10.1155/2021/4548594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shi Q, Yan X, Wang J, Zhang X. Collagen Family Genes Associated with Risk of Recurrence after Radiation Therapy for Vestibular Schwannoma and Pan-Cancer Analysis. Dis Markers 2021;2021:7897994. [PMID: 34691289 DOI: 10.1155/2021/7897994] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
17 Liu J, Lu J, Li W. A Comprehensive Prognostic and Immunological Analysis of a New Three-Gene Signature in Hepatocellular Carcinoma. Stem Cells Int 2021;2021:5546032. [PMID: 34188686 DOI: 10.1155/2021/5546032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Jiang M, Ren L, Chen Y, Wang H, Wu H, Cheng S, Li G, Yu S. Identification of a Hypoxia-Related Signature for Predicting Prognosis and the Immune Microenvironment in Bladder Cancer. Front Mol Biosci 2021;8:613359. [PMID: 34026819 DOI: 10.3389/fmolb.2021.613359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Chacon AC, Melucci AD, Qin SS, Prieto PA. Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. Int J Mol Sci 2021;22:3228. [PMID: 33810078 DOI: 10.3390/ijms22063228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Shahmoradi M, Rezvani Z. Functional Prediction of Long Noncoding RNAs in Cutaneous Melanoma Using a Systems Biology Approach. Bioinform Biol Insights 2021;15:1177932220988508. [PMID: 33613027 DOI: 10.1177/1177932220988508] [Reference Citation Analysis]
21 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 37.0] [Reference Citation Analysis]
22 Chong W, Shang L, Liu J, Fang Z, Du F, Wu H, Liu Y, Wang Z, Chen Y, Jia S, Chen L, Li L, Chen H. m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. Theranostics 2021;11:2201-17. [PMID: 33500720 DOI: 10.7150/thno.52717] [Cited by in Crossref: 78] [Cited by in F6Publishing: 87] [Article Influence: 39.0] [Reference Citation Analysis]
23 Chong W, Wang Z, Shang L, Jia S, Liu J, Fang Z, Du F, Wu H, Liu Y, Chen Y, Chen H. Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC. Mol Ther Nucleic Acids 2021;23:89-100. [PMID: 33335795 DOI: 10.1016/j.omtn.2020.10.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
24 Li X, Wen D, Li X, Yao C, Chong W, Chen H. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer. Front Immunol 2020;11:1678. [PMID: 33013820 DOI: 10.3389/fimmu.2020.01678] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
25 Chong W, Zhang H, Guo Z, Yang L, Shao Y, Liu X, Zhao Y, Wang Z, Zhang M, Guo C, Fu L, Ma Y, Gu F. Aquaporin 1 promotes sensitivity of anthracycline chemotherapy in breast cancer by inhibiting β-catenin degradation to enhance TopoIIα activity. Cell Death Differ 2021;28:382-400. [PMID: 32814878 DOI: 10.1038/s41418-020-00607-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
26 Zhang Q, Wang J, Liu M, Zhu Q, Li Q, Xie C, Han C, Wang Y, Gao M, Liu J. Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2020;12:13502-17. [PMID: 32644941 DOI: 10.18632/aging.103454] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
27 Jin J, Zhao Q. Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. Theranostics 2020;10:6231-44. [PMID: 32483450 DOI: 10.7150/thno.45219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]